Logo image of CRIS

CURIS INC (CRIS) Stock Fundamental Analysis

NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD

3.1  0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRIS. CRIS was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of CRIS have multiple concerns. CRIS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRIS has reported negative net income.
CRIS had a negative operating cash flow in the past year.
In the past 5 years CRIS always reported negative net income.
CRIS had a negative operating cash flow in each of the past 5 years.
CRIS Yearly Net Income VS EBIT VS OCF VS FCFCRIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

CRIS has a Return On Assets of -107.09%. This is in the lower half of the industry: CRIS underperforms 77.98% of its industry peers.
Industry RankSector Rank
ROA -107.09%
ROE N/A
ROIC N/A
ROA(3y)-47.14%
ROA(5y)-49.53%
ROE(3y)-137.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRIS Yearly ROA, ROE, ROICCRIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

The Gross Margin of CRIS (98.68%) is better than 97.87% of its industry peers.
CRIS's Gross Margin has been stable in the last couple of years.
CRIS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y0.68%
CRIS Yearly Profit, Operating, Gross MarginsCRIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

1

2. Health

2.1 Basic Checks

CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRIS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRIS has been increased compared to 5 years ago.
CRIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRIS Yearly Shares OutstandingCRIS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
CRIS Yearly Total Debt VS Total AssetsCRIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

CRIS has an Altman-Z score of -43.57. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CRIS (-43.57) is worse than 93.78% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -43.57
ROIC/WACCN/A
WACC9.44%
CRIS Yearly LT Debt VS Equity VS FCFCRIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

CRIS has a Current Ratio of 1.22. This is a normal value and indicates that CRIS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.22, CRIS is doing worse than 85.26% of the companies in the same industry.
A Quick Ratio of 1.22 indicates that CRIS should not have too much problems paying its short term obligations.
CRIS's Quick ratio of 1.22 is on the low side compared to the rest of the industry. CRIS is outperformed by 83.66% of its industry peers.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 1.22
CRIS Yearly Current Assets VS Current LiabilitesCRIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.29% over the past year.
Looking at the last year, CRIS shows a small growth in Revenue. The Revenue has grown by 0.38% in the last year.
Measured over the past years, CRIS shows a decrease in Revenue. The Revenue has been decreasing by -0.79% on average per year.
EPS 1Y (TTM)16.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.19%
Revenue 1Y (TTM)0.38%
Revenue growth 3Y-2.58%
Revenue growth 5Y-0.79%
Sales Q2Q%3.46%

3.2 Future

The Earnings Per Share is expected to grow by 12.94% on average over the next years. This is quite good.
CRIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.27% yearly.
EPS Next Y21%
EPS Next 2Y22.11%
EPS Next 3Y15.33%
EPS Next 5Y12.94%
Revenue Next Year-6.38%
Revenue Next 2Y-11.34%
Revenue Next 3Y0.93%
Revenue Next 5Y43.27%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRIS Yearly Revenue VS EstimatesCRIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M
CRIS Yearly EPS VS EstimatesCRIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRIS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRIS Price Earnings VS Forward Price EarningsCRIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIS Per share dataCRIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

CRIS's earnings are expected to grow with 15.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.11%
EPS Next 3Y15.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRIS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CURIS INC

NASDAQ:CRIS (2/21/2025, 8:10:54 PM)

3.1

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2025-02-06/amc
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners37.99%
Inst Owner Change-79.73%
Ins Owners7.81%
Ins Owner Change0%
Market Cap26.26M
Analysts80
Price Target21.42 (590.97%)
Short Float %2.11%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.69%
Min EPS beat(2)-42.45%
Max EPS beat(2)-18.94%
EPS beat(4)2
Avg EPS beat(4)-12.56%
Min EPS beat(4)-42.45%
Max EPS beat(4)5.86%
EPS beat(8)5
Avg EPS beat(8)-5.42%
EPS beat(12)6
Avg EPS beat(12)-4.4%
EPS beat(16)7
Avg EPS beat(16)-5.44%
Revenue beat(2)2
Avg Revenue beat(2)23.56%
Min Revenue beat(2)20.95%
Max Revenue beat(2)26.17%
Revenue beat(4)2
Avg Revenue beat(4)4.89%
Min Revenue beat(4)-15%
Max Revenue beat(4)26.17%
Revenue beat(8)3
Avg Revenue beat(8)-0.52%
Revenue beat(12)4
Avg Revenue beat(12)-2.96%
Revenue beat(16)6
Avg Revenue beat(16)-3.03%
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)-15.99%
EPS NQ rev (3m)11.34%
EPS NY rev (1m)0%
EPS NY rev (3m)1.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.81
EYN/A
EPS(NY)-4.56
Fwd EYN/A
FCF(TTM)-4.78
FCFYN/A
OCF(TTM)-4.78
OCFYN/A
SpS1.21
BVpS-1.03
TBVpS-2.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.68%
FCFM N/A
ROA(3y)-47.14%
ROA(5y)-49.53%
ROE(3y)-137.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y0.68%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.22
Quick Ratio 1.22
Altman-Z -43.57
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)60.87%
Cap/Depr(5y)139.82%
Cap/Sales(3y)1.38%
Cap/Sales(5y)2.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.19%
EPS Next Y21%
EPS Next 2Y22.11%
EPS Next 3Y15.33%
EPS Next 5Y12.94%
Revenue 1Y (TTM)0.38%
Revenue growth 3Y-2.58%
Revenue growth 5Y-0.79%
Sales Q2Q%3.46%
Revenue Next Year-6.38%
Revenue Next 2Y-11.34%
Revenue Next 3Y0.93%
Revenue Next 5Y43.27%
EBIT growth 1Y-2.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.79%
EBIT Next 3Y-6.28%
EBIT Next 5Y-9.65%
FCF growth 1Y20.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.41%
OCF growth 3YN/A
OCF growth 5YN/A